AVE1231 - 98%, high purity , CAS No.767334-89-4, Channel blocker of K 2P3.1

Item Number

A607819

Grouped product items
SKU	Size	Availability	Price
A607819-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$699.90
A607819-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$999.90
A607819-50mg	50mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,359.90
A607819-100mg	100mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,899.90

View related series

Basic Description

Synonyms	VGZ6BSQ5DR\|AVE1231\|A-293\|UNII-VGZ6BSQ5DR\|767334-89-4\|Benzamide, 2-((butylsulfonyl)amino)-N-((1R)-1-(6-methoxy-3-pyridinyl)propyl)-\|2-(butylsulfonylamino)-N-[(1R)-1-(6-methoxypyridin-3-yl)propyl]benzamide\|(R)-2-(Butylsulfonamido)-N-(1-(6-methoxypyridin-3-y
Specifications & Purity	98%
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	CHANNEL BLOCKER
Mechanism of action	Channel blocker of K 2P3.1
Product Description	AVE1231 is an atrial-selective antiarrhythmic human cardiac Kv1.5 inhibitor.

Names and Identifiers

IUPAC Name	2-(butylsulfonylamino)-N-[(1R)-1-(6-methoxypyridin-3-yl)propyl]benzamide
INCHI	InChI=1S/C20H27N3O4S/c1-4-6-13-28(25,26)23-18-10-8-7-9-16(18)20(24)22-17(5-2)15-11-12-19(27-3)21-14-15/h7-12,14,17,23H,4-6,13H2,1-3H3,(H,22,24)/t17-/m1/s1
InChi Key	BFQMQSIBOHOPCY-QGZVFWFLSA-N
Canonical SMILES	CCCCS(=O)(=O)Nc1ccccc1C(=O)N[C@@H](c1ccc(nc1)OC)CC
Isomeric SMILES	CCCCS(=O)(=O)NC1=CC=CC=C1C(=O)N[C@H](CC)C2=CN=C(C=C2)OC
PubChem CID	9844211
Molecular Weight	405.51

PubChem CID

CAS Registry No.

Certificates

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

8 results found

Lot Number	Certificate Type	Date	Item
F2420333	Certificate of Analysis	Mar 13, 2024	A607819
F2420335	Certificate of Analysis	Mar 13, 2024	A607819
F2420337	Certificate of Analysis	Mar 13, 2024	A607819
F2420346	Certificate of Analysis	Mar 13, 2024	A607819
F2420347	Certificate of Analysis	Mar 13, 2024	A607819
F2420357	Certificate of Analysis	Mar 13, 2024	A607819
F2420368	Certificate of Analysis	Mar 13, 2024	A607819
F2420413	Certificate of Analysis	Mar 13, 2024	A607819

References

1. Wirth KJ, Brendel J, Steinmeyer K, Linz DK, Rütten H, Gögelein H. (2007) In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231.. J Cardiovasc Pharmacol, 49 (4): (197-206). [PMID:17438404]
2. Ehrlich JR, Ocholla H, Ziemek D, Rütten H, Hohnloser SH, Gögelein H. (2008) Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.. J Cardiovasc Pharmacol, 51 (4): (380-7). [PMID:18427281]
3. Shvetsova AA, Gaynullina DK, Schmidt N, Bugert P, Lukoshkova EV, Tarasova OS, Schubert R. (2020) TASK-1 channel blockade by AVE1231 increases vasocontractile responses and BP in 1- to 2-week-old but not adult rats.. Br J Pharmacol, 177 (22): (5148-5162). [PMID:32860629]
4. Wiedmann F, Kiper AK, Bedoya M, Ratte A, Rinné S, Kraft M, Waibel M, Anad P, Wenzel W, González W et al.. (2019) Identification of the A293 (AVE1231) Binding Site in the Cardiac Two-Pore-Domain Potassium Channel TASK-1: a Common Low Affinity Antiarrhythmic Drug Binding Site.. Cell Physiol Biochem, 52 (5): (1223-1235). [PMID:31001961]

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description